WallStSmart

Agilent Technologies Inc (A)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 732% more annual revenue ($61.37B vs $7.37B). A leads profitability with a 19.5% profit margin vs 17.0%. A appears more attractively valued with a PEG of 1.25. A earns a higher WallStSmart Score of 63/100 (C+).

A

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 8.5Value: 4.7Quality: 6.0
Piotroski: 3/9Altman Z: 1.99

AZN

Buy

60

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 6.7Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-66.4%)

Margin of Safety

-66.4%

Fair Value

$77.48

Current Price

$146.93

$69.45 premium

UndervaluedFair: $77.48Overvalued
AZNUndervalued (+18.4%)

Margin of Safety

+18.4%

Fair Value

$196.10

Current Price

$160.17

$35.93 discount

UndervaluedFair: $196.10Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A1 strengths · Avg: 8.0/10
Operating MarginProfitability
25.6%8/10

Strong operational efficiency at 25.6%

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$252.33B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
20.8%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
23.5%8/10

Strong operational efficiency at 23.5%

Free Cash FlowQuality
$2.13B8/10

Generating 2.1B in free cash flow

Areas to Watch

A3 concerns · Avg: 3.7/10
P/E RatioValuation
29.0x4/10

Moderate valuation

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

AZN2 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.5%4/10

2.5% earnings growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on Operating Margin. Profitability is solid with margins at 19.5% and operating margin at 25.6%. PEG of 1.25 suggests the stock is reasonably priced for its growth.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.

Bear Case : A

The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.

Bear Case : AZN

The primary concerns for AZN are EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

A carries more volatility with a beta of 1.24 — expect wider price swings.

A is growing revenue faster at 8.1% — sustainability is the question.

AZN generates stronger free cash flow (2.1B), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

A scores higher overall (63/100 vs 60/100), backed by strong 19.5% margins. AZN offers better value entry with a 18.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?